Nebispes (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebispes, is a beta blocker presented as an oral formulation for oral use. It lowers elevated blood pressure and is indicated for the management of hypertension in adult patients.

GNH USA supplies Nebispes as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is marketed for prescription use.

Nebivolol is a selective β1‑adrenergic antagonist used in cardiovascular therapy.

- Hypertension: reduces systolic and diastolic blood pressure, decreasing cardiovascular risk. - Heart failure: improves left‑ventricular ejection fraction and symptoms in patients with reduced‑ejection‑fraction heart failure. - Chronic stable angina (off‑label in some regions): may alleviate chest pain by improving myocardial oxygen supply.

Nebivolol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or general weakness. - Nausea or mild gastrointestinal upset. - Bradycardia: heart rate slower than normal. - Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Acute bronchospasm in patients with asthma or COPD. - Allergic reactions such as rash, pruritus, or angio‑edema. - Hepatic dysfunction or elevated liver enzymes. - Cardiogenic shock in patients with advanced heart failure.

Before initiating Nebispes, clinicians should evaluate patient history and monitor relevant parameters.

- Blood pressure monitoring: ensure adequate control and avoid hypotension. - Cardiac function assessment: review for existing heart block or severe bradycardia. - Respiratory disease caution: use carefully in asthma or COPD patients. - Concomitant beta‑blocker use: avoid additive effects that may cause excessive heart rate reduction. - Renal or hepatic impairment: dose adjustment may be required. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other beta‑blockers: additive negative chronotropic effects. - Calcium‑channel blockers (verapamil, diltiazem): increased risk of AV‑block and bradycardia. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): may raise nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - Clonidine withdrawal: abrupt cessation can cause rebound hypertension. - Insulin or oral hypoglycemics: nebivolol may mask hypoglycemia symptoms.